Thursday, June 8, 2023
News Media Empire
  • About Us
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Home
  • World News
  • Politics
  • Business & Economy
  • Money
  • Science & Tech
  • Opinion
  • Lifestyle
  • Health
  • Sports
  • Entertainment
  • Crypto
No Result
View All Result
  • Home
  • World News
  • Politics
  • Business & Economy
  • Money
  • Science & Tech
  • Opinion
  • Lifestyle
  • Health
  • Sports
  • Entertainment
  • Crypto
No Result
View All Result
News Media Empire
No Result
View All Result
Home Health

AstraZeneca’s antibody cocktail failed to prevent COVID-19 symptoms in large trial

June 15, 2021
in Health
0
AstraZeneca’s antibody cocktail failed to prevent COVID-19 symptoms in large trial
0
SHARES
Share on FacebookShare on TwitterShare on RedditShare on Whatsapp


AstraZeneca said on Tuesday a late-stage trial failed to provide evidence that its COVID-19 antibody therapy protected people who had contact with an infected person from the disease, a small setback in its efforts to find alternatives to vaccines.

The study assessed whether the therapy, a cocktail of two types of antibodies, could prevent adults who had been exposed to the virus in the past eight days from developing COVID-19 symptoms.

Get Free Advertise Coin

The therapy, AZD7442, was 33 per cent effective in reducing the risk of people developing symptoms compared with a placebo, but that result was not statistically significant — meaning it might have been due to chance and not the therapy.

Read more:
Researchers hope manufactured antibodies could help treat COVID-19

The Phase III study, which has not been peer-reviewed, included 1,121 participants in the United Kingdom and the United States. The vast majority, though not all, were free of the virus at the start of the trial.

Story continues below advertisement

Results for a subset of participants who were not infected to begin with was more encouraging but the primary analysis rested on results from all participants.

“While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen in the PCR negative participants following treatment with AZD7442,” AstraZeneca Executive Vice President Mene Pangalos said in a statement.

The company is banking on further studies to revive the product’s fortunes. Five more trials are ongoing, testing the antibody cocktail as treatment or in prevention.

The next one will likely be from a larger trial testing the product in people with a weakened immune system due to cancer or an organ transplant, who may not benefit from a vaccine.

Trending Stories


  • 2 Pfizer COVID-19 vaccines more effective than AstraZeneca against Delta variant, data says


  • Witness describes events leading up to fatal 2019 boat crash involving Linda, Kevin O’Leary

 

AZD7442 belongs to a class of drugs called monoclonal antibodies which mimic natural antibodies produced by the body to fight off infections.

Story continues below advertisement

Similar therapies developed by rivals Regeneron and Eli Lilly have been approved by U.S. regulators for treating unhospitalised COVID patients.

European regulators have also authorized Regeneron’s therapy and are reviewing those developed by partners GlaxoSmithKline and Vir Biotechnology as well as by Lilly and Celltrion.

Regeneron is also seeking U.S. authorisation for its therapy as a preventative treatment.


Click to play video: 'LifeLabs announces new COVID-19 antibody test for British Columbians'






1:44
LifeLabs announces new COVID-19 antibody test for British Columbians


LifeLabs announces new COVID-19 antibody test for British Columbians – Nov 26, 2020

But the AstraZeneca results are a small blow for the drug industry as it tries to find more targeted alternatives to COVID-19 inoculations, particularly for people who may not be able to get vaccinated or those who may have an inadequate response to inoculations.

The Anglo-Swedish drugmaker, which has faced a rollercoaster of challenges with the rollout of its COVID-19 vaccine, is also developing new treatments and repurposing existing drugs to fight the virus.

Story continues below advertisement

AstraZeneca also said on Tuesday it was in talks with the U.S. government on “next steps” regarding a $205 million deal to supply up to 500,000 doses of AZD7442. Swiss manufacturer Lonza was contracted to produce AZD7442.

Shares in the company were largely unchanged on the London Stock Exchange.








Source link

Tags: HealthWorld
Previous Post

Debt? Modern Monetary Theory says government can have it all

Next Post

Biden, EU leaders vow to restore relations after Trump tension

Related Posts

Canada’s drug pricing conflict sparked by health minister letter, emails show - National | Globalnews.ca
Health

Canada’s drug pricing conflict sparked by health minister letter, emails show – National | Globalnews.ca

June 8, 2023
How 'severe and unusual' smoke from Canadian wildfires is spreading and what it means for your health | CBC News
Health

How ‘severe and unusual’ smoke from Canadian wildfires is spreading and what it means for your health | CBC News

June 7, 2023
Wildfires pose health risk to pregnancy, experts warn. Here’s what to know - National | Globalnews.ca
Health

Wildfires pose health risk to pregnancy, experts warn. Here’s what to know – National | Globalnews.ca

June 7, 2023
Next Post
Biden, EU leaders vow to restore relations after Trump tension

Biden, EU leaders vow to restore relations after Trump tension

Supermarket comparison website will tell you cheapest place to buy weekly shop

Supermarket comparison website will tell you cheapest place to buy weekly shop

ACDP Rev Kenneth Meshoe holding a  service outside church.  Photo by Zamokuhle Mdluli

Siya Khumalo | Church, could the ACDP be your biggest business risk? | News24

Discussion about this post

AdvertiseCoin ADCO Get Now Free
News Media Empire

Newsmediaempire is an online news source that provides the latest news and other information about everything that you must need to know. It publishes news related to various fields like world, business, sports, politics, tech, health, lifestyle, and other different exclusive stories.

Let's connect!

Categories

  • Business & Economy
  • Crypto
  • Entertainment
  • Health
  • Lifestyle
  • Money
  • Opinion
  • Politics
  • Science & Tech
  • Sports
  • World News

Recent News

  • Banyana players who make World Cup cut in line for at least R570k FIFA pay day | Sport June 8, 2023
  • Govt insists race-based water licences are only for new applicants – but farmers disagree | Business June 8, 2023
  • Breaking: Terra Classic’s Biggest v2.1.0 Parity Upgrade Proposal Officially Passed, LUNC To $1 June 8, 2023

Join Our Newsletter!

    • About Us
    • Contact
    • Privacy Policy
    • Terms & Conditions

    newsmediaempire.com © 2021 All rights reserved.

    No Result
    View All Result
    • About Us
    • Contact
    • Home 1
    • Home 2
    • Home 3
    • Privacy Policy
    • Random
    • Sample Page
    • Terms & Conditions

    newsmediaempire.com © 2021 All rights reserved.

    en English
    ar Arabicbg Bulgarianzh-CN Chinese (Simplified)nl Dutchen Englishfr Frenchde Germanit Italianpt Portugueseru Russianes Spanish
    This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.